Daniel B. Longley

15.9k citations

126 papers · 12.1k indexed · 2 hit papers · h-index 42

Impact in

Oncology top 0.2%
- Colorectal Cancer Treatments and Studies
- Cancer-related Molecular Pathways
- Cancer Cells and Metastasis
Cancer Research top 0.5%

Papers in

Oncology 69
- Colorectal Cancer Treatments and Studies 33
- Cancer-related Molecular Pathways 24
- Cancer Immunotherapy and Biomarkers 7
Molecular Biology 83
- Cell death mechanisms and regulation 42
- Ubiquitin and proteasome pathways 8

Co-authors: Patrick G. Johnston D. Paul Harkin Sandra Van Schaeybroeck Caitriona Holohan Wendy L. Allen Timothy R. Wilson Nyree Crawford Ultan McDermott
Journals: Molecular Cancer Therapeutics (12 papers)Clinical Cancer Research (11 papers)Cell Death and Disease (10 papers)Cancer Research (8 papers)Cell Death and Differentiation (5 papers)
Partner nations: United Kingdom Ireland United States

In The Last Decade

Daniel B. Longley

124 papers receiving 12.0k citations

Hit Papers

align trajectories log scale

Cancer drug resistance: an evolving paradigm 2013 · 3.6k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2013 Nature reviews. Cancer
2003 Nature reviews. Cancer

Peers

Countries citing papers authored by Daniel B. Longley

Since Specialization

Citations

This map shows the geographic impact of Daniel B. Longley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel B. Longley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel B. Longley more than expected).

Fields of papers citing papers by Daniel B. Longley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel B. Longley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel B. Longley. The network helps show where Daniel B. Longley may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Daniel B. Longley, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Daniel B. Longley Line = papers co-authored together Daniel B. Longley links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Chemical- and photo-activation of protein-protein thiol-ene coupling for protein profiling Communications Chemistry ·Nakatani Hidehito, Marcin Baran, Andrew Bowie, Daniel B. Longley, Timothy Harrison, Joanna F. McGouran	2025	1
2	USP7 inhibitors suppress tumour neoangiogenesis and promote synergy with immune checkpoint inhibitors by downregulating fibroblast VEGF Clinical and Translational Medicine ·Anushka Kothari, عبدالله بوروة, Mark Wappett, Julien Daubriac, Ian Lobb, Garcés Estefanía, Nyree Crawford, Natalie Page, Fiolita Etsa Aurora, Ilaria Pina, Diana E. Hernandez-Jimenez, Matthew Helm, C. O'Dowd, Richard D. Kennedy, Gérald Gavory, Aaron Cranston, Daniel B. Longley, Xavier Jacq, Timothy Harrison	2024	9
3	TNF-α synergises with IFN-γ to induce caspase-8-JAK1/2-STAT1-dependent death of intestinal epithelial cells Cell Death and Disease ·Jerzy A. Woznicki, Atilla Ceranoglu, Peter F. Flood, Siti Zumrotin, Ciaran M. Lee, Panagiota Stamou, Linda MacLeod, 山岡英介, Karine Regazzoni, Nyree Crawford, Simon S. McDade, Daniel B. Longley, Pedro Aza‐Blanc, Fergus Shanahan, Anke Griesinger, Jane McCarthy, Silvia Melgar, Bradford L. McRae, Kenneth Nally	2021	109
4	Epithelial‐to‐mesenchymal transition signature assessment in colorectal cancer quantifies tumour stromal content rather than true transition The Journal of Pathology ·Amy M.B. McCorry, Maurice B. Loughrey, Daniel B. Longley, Mark Lawler, Philip D. Dunne	2018	18
5	Immune-Derived PD-L1 Gene Expression Defines a Subgroup of Stage II/III Colorectal Cancer Patients with Favorable Prognosis Who May Be Harmed by Adjuvant Chemotherapy Cancer Immunology Research ·Philip D. Dunne, Darragh G. McArt, Paul G. O’Reilly, Helen G. Coleman, Wendy L. Allen, Maurice B. Loughrey, Sandra Van Schaeybroeck, Simon S. McDade, Manuel Salto‐Tellez, Daniel B. Longley, Mark Lawler, Patrick G. Johnston	2016	31
6	Challenging the Cancer Molecular Stratification Dogma: Intratumoral Heterogeneity Undermines Consensus Molecular Subtypes and Potential Diagnostic Value in Colorectal Cancer Clinical Cancer Research ·Philip D. Dunne, Darragh G. McArt, Conor A. Bradley, Paul G. O’Reilly, Helen L. Barrett, Robert Cummins, J. C. Lee, Ken Arthur, Maurice B. Loughrey, Wendy L. Allen, Simon S. McDade, David Waugh, Peter W. Hamilton, Daniel B. Longley, Elaine W. Kay, Patrick G. Johnston, Mark Lawler, Manuel Salto‐Tellez, Sandra Van Schaeybroeck	2016	103
7	FLIP: A Targetable Mediator of Resistance to Radiation in Non–Small Cell Lung Cancer Molecular Cancer Therapeutics ·Cecilie Moe, Erica Chinzer, Conor A. Bradley, Tugce Miroglu Guler, HexCam, Annabelle Roth, Joanna Majkut, Catherine Higgins, Nyree Crawford, Caitriona Holohan, Patrick G. Johnston, Timothy Harrison, Gerard G. Hanna, Karl T. Butterworth, Kevin M. Prise, Daniel B. Longley	2016	19
8	HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF -Mutant Colorectal Cancer by Downregulation of c-FLIPL Clinical Cancer Research ·S. Kesek, K. Kelm, Jeffrey R. Root, A. Bader, Nyree Crawford, Lucía Pérez–Carbonell, Mark Lawler, Daniel B. Longley, Patrick G. Johnston, Sandra Van Schaeybroeck	2015	55
9	AXL Is a Key Regulator of Inherent and Chemotherapy-Induced Invasion and Predicts a Poor Clinical Outcome in Early-Stage Colon Cancer Clinical Cancer Research ·Philip D. Dunne, Darragh G. McArt, Jaine K. Blayney, Murugan Kalimutho, Jessica Ignatia Tambunan, Tingting Wang, Supriya Srivastava, Chee Wee Ong, Ken Arthur, Maurice B. Loughrey, Keara L. Redmond, Daniel B. Longley, Manuel Salto‐Tellez, Patrick G. Johnston, Sandra Van Schaeybroeck	2013	89
10	Elevation of c-FLIP in Castrate-Resistant Prostate Cancer Antagonizes Therapeutic Response to Androgen Receptor–Targeted Therapy Clinical Cancer Research ·O.A. Dyudyaeva, Pamela Maxwell, Roberta Mazzucchelli, Rodolfo Montironi, Marina Scarpelli, Manuel Salto‐Tellez, Joe M. O’Sullivan, Daniel B. Longley, David Waugh	2012	51
11	Pharmacogenomic Profiling and Pathway Analyses Identify MAPK-Dependent Migration as an Acute Response to SN38 in p53 Null and p53-Mutant Colorectal Cancer Cells Molecular Cancer Therapeutics ·Wendy L. Allen, Richard Turkington, Leanne Stevenson, أ.م.د. مروان سالم علي, Vicky M. Coyle, Suzanne Hector, Philip D. Dunne, Sandra Van Schaeybroeck, Daniel B. Longley, Patrick G. Johnston	2012	7
12	Identification of Galanin and Its Receptor GalR1 as Novel Determinants of Resistance to Chemotherapy and Potential Biomarkers in Colorectal Cancer Clinical Cancer Research ·Leanne Stevenson, Wendy L. Allen, Richard Turkington, Puthen V. Jithesh, Irina Proutski, Gail Stewart, Heinz‐Josef Lenz, Sandra Van Schaeybroeck, Daniel B. Longley, Patrick G. Johnston	2012	49
13	A Systems Biology Approach Identifies SART1 as a Novel Determinant of Both 5-Fluorouracil and SN38 Drug Resistance in Colorectal Cancer Molecular Cancer Therapeutics ·Wendy L. Allen, Leanne Stevenson, Vicky M. Coyle, Puthen V. Jithesh, Irina Proutski, أ.م.د. مروان سالم علي, Michael A. Gordon, Atsuko Watanabe, Sandra Van Schaeybroeck, Daniel B. Longley, Patrick G. Johnston	2011	30
14	Prognostic Significance of TRAIL Signaling Molecules in Stage II and III Colorectal Cancer Clinical Cancer Research ·Donal P. McLornan, Helen L. Barrett, Robert Cummins, Ultan McDermott, Clíona McDowell, М Л Репкин, Victoria Coyle, Sandra Van Schaeybroeck, Richard H. Wilson, Elaine W. Kay, Daniel B. Longley, Patrick G. Johnston	2010	64
15	Oncogenic Kras Promotes Chemotherapy-Induced Growth Factor Shedding via ADAM17 Cancer Research ·Sandra Van Schaeybroeck, Joan Kyula, Amanda D. Ellis, Annabelle Roth, Takehiko Sasazuki, Senji Shirasawa, Daniel B. Longley, Patrick G. Johnston	2010	39
16	Chemotherapy-Induced Activation of ADAM-17: A Novel Mechanism of Drug Resistance in Colorectal Cancer Clinical Cancer Research ·Joan Kyula, Sandra Van Schaeybroeck, Shuyi Kui, Annabelle Roth, Daniel B. Longley, Patrick G. Johnston	2010	83
17	Prostate-derived factor—a novel inhibitor of drug-induced cell death in colon cancer cells Molecular Cancer Therapeutics ·Irina Proutski, Leanne Stevenson, Wendy L. Allen, Andrea McCulla, John Boyer, Estelle G. McLean, Daniel B. Longley, Patrick G. Johnston	2009	18
18	Clinical Determinants of Response to Irinotecan-Based Therapy Derived from Cell Line Models Clinical Cancer Research ·Wendy L. Allen, Vicky M. Coyle, Puthen V. Jithesh, Irina Proutski, Leanne Stevenson, Jeffrey R. Root, Daniel B. Longley, Richard H. Wilson, Michael A. Gordon, Heinz‐Josef Lenz, Patrick G. Johnston	2008	17
19	Pharmacogenomic Identification of Novel Determinants of Response to Chemotherapy in Colon Cancer Cancer Research ·John Boyer, Wendy L. Allen, Estelle G. McLean, Peter M. Wilson, Andrea McCulla, C. Soellner, Daniel B. Longley, Carlos Caldas, Patrick G. Johnston	2006	87
20	5-Fluorouracil: identification of novel downstream mediators of tumour response. PubMed ·John Boyer, Pamela Maxwell, Daniel B. Longley, Patrick G. Johnston	2004	16

About Daniel B. Longley

Daniel B. Longley is a scholar working on Oncology, Molecular Biology, Pathology and Forensic Medicine, Cancer Research and Immunology, having authored 126 papers that have together received 12.1k indexed citations. Recurring topics across this work include Cell death mechanisms and regulation (42 papers), Colorectal Cancer Treatments and Studies (33 papers), Cancer-related Molecular Pathways (24 papers), Genetic factors in colorectal cancer (16 papers), Ubiquitin and proteasome pathways (8 papers), Cancer Immunotherapy and Biomarkers (7 papers), Phagocytosis and Immune Regulation (7 papers) and interferon and immune responses (6 papers). The work is most often cited by research in Oncology (4.7k citations), Cancer Research (2.1k citations), Molecular Biology (7.0k citations), Biomaterials (999 citations) and Pathology and Forensic Medicine (1.1k citations). Daniel B. Longley has collaborated with scholars based in United Kingdom, Ireland and United States. Frequent co-authors include Patrick G. Johnston, D. Paul Harkin, Sandra Van Schaeybroeck, Caitriona Holohan, Wendy L. Allen, Timothy R. Wilson, Nyree Crawford, Ultan McDermott, Leeona Galligan and Kirsty M. McLaughlin. Their work appears in journals such as Molecular Cancer Therapeutics, Clinical Cancer Research, Cell Death and Disease, Cancer Research and Cell Death and Differentiation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact